KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Return on Sales (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Return on Sales data on record, last reported at 0.06% in Q4 2025.

  • For Q4 2025, Return on Sales rose 9.0% year-over-year to 0.06%; the TTM value through Dec 2025 reached 0.04%, up 7.0%, while the annual FY2025 figure was 0.04%, 7.0% up from the prior year.
  • Return on Sales reached 0.06% in Q4 2025 per AMRX's latest filing, up from 0.02% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.06% in Q4 2025 and bottomed at 0.43% in Q2 2022.
  • Average Return on Sales over 5 years is 0.02%, with a median of 0.01% recorded in 2024.
  • Peak YoY movement for Return on Sales: tumbled -49bps in 2022, then surged 48bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 0.04% in 2021, then skyrocketed by 75bps to 0.01% in 2022, then plummeted by -1485bps to 0.15% in 2023, then surged by 81bps to 0.03% in 2024, then skyrocketed by 314bps to 0.06% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 0.06% in Q4 2025, 0.02% in Q3 2025, and 0.05% in Q2 2025.